COMMUNIQUÉS West-GlobeNewswire

Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
28/05/2024
LEXINGTON, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Merus N.V. Announces Proposed Public Offering of Common Shares
28/05/2024
UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length [...]
Cytokinetics Announces Closing of Public Offering of Common Stock
28/05/2024
SOUTH SAN FRANCISCO, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously announced underwritten public offering of 9,803,922 shares of its [...]
Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes
28/05/2024
Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls [...]
Annual General Meeting of Ipsen S.A. held on 28 May 2024
28/05/2024
All the resolutions submitted to the shareholders’ vote have been adopted PARIS, FRANCE, 28 May 2024 - The Annual General Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY) was held today at the Salons de l'Hôtel des [...]
Assemblée Générale Annuelle d’Ipsen S.A. du 28 mai 2024
28/05/2024
Toutes les résolutions soumises au vote des actionnaires ont été adoptées PARIS, FRANCE, 28 mai 2024 - L’Assemblée Générale Annuelle de la société IPSEN S.A. (Euronext : IPN ; ADR : IPSEY) s’est réunie aujourd’hui aux [...]
Altamira Therapeutics Provides Business Update
28/05/2024
Hamilton, Bermuda, May 28, 2024 (GLOBE NEWSWIRE) -- Achieved significant improvement in handling and transport stability of RNA nanoparticles Pursuing partnering opportunities with AM-125 legacy asset in vertigo and / [...]
IntelGenx Obtains Court-Approval of a Sale and Investment Solicitation Process
28/05/2024
MONTREAL, May 28, 2024 (GLOBE NEWSWIRE) -- As previously announced on May 17, 2024, IntelGenx Technologies Corp. (the “ Company ” or “ IntelGenx ”) (OCTQB: IGXT; TSX: IGX), a leading drug delivery company focused on the [...]
Mithra postpones its annual general meeting
28/05/2024
Liege, Belgium, 28 May 2024 – 15:00 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to women’s health, today announces that in the context of the monetization process and the uncertainties related thereto [...]
Aviv Clinics Spotlights New Study Using Hyperbaric Oxygen Therapy for Adults Suffering from Fibromyalgia Related to Childhood Sexual Abuse
28/05/2024
Study finds hyperbaric oxygen therapy exceeds pharmacological intervention in improvement of generalized pain and physical symptoms, emotional state and daily functioning in individuals with childhood sexual abuse [...]
Precision Neuroscience Announces World Record for Number of Electrodes Placed On Human Brain
28/05/2024
In a recent clinical study, Precision recorded human brain activity from over four thousand electrodes, allowing streaming of real-time cortical data for visualization of brain activity NEW YORK, May 28, 2024 (GLOBE [...]
InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024
28/05/2024
Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial Study results to support a Premarket Approval ( [...]
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
28/05/2024
ATRN-119 is the first and only macrocyclic ATR inhibitor in the clinic, with best in class potential On track to complete dose escalation in ABOYA-119 clinical trial and potentially generate initial human efficacy data [...]
Workhorse Health Introduces Innovative Mental Health Services for Ontario's Caregivers and Their Families
28/05/2024
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Workhorse Health is on a mission to bridge the gap in mental health services by providing support for those navigating the challenges of caregiving. They have become the first [...]
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma
28/05/2024
The analysis published in Clinical Ophthalmology suggests that OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma as it was in mild and moderate glaucoma. MENLO PARK, Calif., May 28 [...]
CytoDyn to Host Webcast to Provide Company Update
28/05/2024
VANCOUVER, Washington, May 28, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple [...]
Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting
28/05/2024
VANCOUVER, British Columbia, May 28, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced data presentations highlighting azetukalner (XEN1101) [...]
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
28/05/2024
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
CorMedix Inc. Announces Commercial Agreement With Top Tier Dialysis Provider
28/05/2024
BERKELEY HEIGHTS, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic products for life-threatening diseases and conditions, today announced [...]

Pages